Thrivent Financial for Lutherans
CTKB icon

Thrivent Financial for Lutherans’s Cytek Biosciences CTKB Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Sell
73,399
-2,161
-3% -$10.2K ﹤0.01% 2359
2025
Q4 		$382K Sell
75,560
-3,374
-4% -$15.7K ﹤0.01% 2344
2025
Q3 		$274K Buy
78,934
+3,495
+5% +$13.1K ﹤0.01% 2253
2025
Q2 		$256K Sell
75,439
-1,199
-2% -$4K ﹤0.01% 2342
2025
Q1 		$307K Sell
76,638
-4,009
-5% -$20.8K ﹤0.01% 2222
2024
Q4 		$523K Sell
80,647
-3,001
-4% -$17.9K ﹤0.01% 2238
2024
Q3 		$463K Buy
83,648
+4,096
+5% +$23.2K ﹤0.01% 2273
2024
Q2 		$444K Sell
79,552
-6,290
-7% -$37.8K ﹤0.01% 2267
2024
Q1 		$576K Sell
85,842
-2,329
-3% -$18.4K ﹤0.01% 2178
2023
Q4 		$804K Sell
88,171
-2,880
-3% -$18.1K ﹤0.01% 1973
2023
Q3 		$503K Buy
91,051
+14,479
+19% +$116K ﹤0.01% 2130
2023
Q2 		$654K Buy
+76,572
New +$687K ﹤0.01% 2064

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Thrivent Financial for Lutherans's CTKB Position: Q1 2026 in Review

Thrivent Financial for Lutherans reduced its Cytek Biosciences (CTKB) stake by 2.9% in Q1 2026, selling an estimated $10.2K and leaving 73,399 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #2359.

Thrivent Financial for Lutherans first reported a position in CTKB in Q2 2023 and has held it in 12 quarters since. The position peaked at $804K in Q4 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Thrivent Financial for Lutherans held 73,399 shares of Cytek Biosciences worth $321K as of Q1 2026.
  • Thrivent Financial for Lutherans sold 2,161 Cytek Biosciences shares in Q1 2026, an estimated $10.2K.
  • Cytek Biosciences made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #2359 holding.
  • Thrivent Financial for Lutherans first reported a position in Cytek Biosciences in Q2 2023 and has held it in 12 quarters since.
  • Thrivent Financial for Lutherans's Cytek Biosciences position peaked at $804K in Q4 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.